DE60134866D1 - Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung - Google Patents

Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung

Info

Publication number: DE60134866D1
Authority: DE; Germany
Prior art keywords: imidazochinolinamines; adjuvanties; dna vaccination; vaccination; dna
Prior art date: 2000-09-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60134866T

Other languages

English (en)

Inventor

Lindy Louise Thomsen

John Philip Tite

Peter Topley

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-20

Filing date

2001-09-20

Publication date

2008-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60134866(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-09-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-08-28 Application granted granted Critical

2008-08-28 Publication of DE60134866D1 publication Critical patent/DE60134866D1/de

2021-09-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE60134866T 2000-09-20 2001-09-20 Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung Expired - Lifetime DE60134866D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0023008.6A GB0023008D0 (en)	2000-09-20	2000-09-20	Improvements in vaccination
PCT/GB2001/004207 WO2002024225A1 (en)	2000-09-20	2001-09-20	Use of immidazoquinolinamines as adjuvants in dna vaccination

Publications (1)

Publication Number	Publication Date
DE60134866D1 true DE60134866D1 (de)	2008-08-28

Family

ID=9899764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60134866T Expired - Lifetime DE60134866D1 (de)	2000-09-20	2001-09-20	Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung

Country Status (24)

Country	Link
US (3)	US20040076633A1 (de)
EP (1)	EP1318835B1 (de)
JP (1)	JP2004509150A (de)
KR (1)	KR100876263B1 (de)
CN (1)	CN1197620C (de)
AR (1)	AR035586A1 (de)
AT (1)	ATE401097T1 (de)
AU (2)	AU8790801A (de)
BR (1)	BR0113982A (de)
CA (1)	CA2422863A1 (de)
CZ (1)	CZ2003792A3 (de)
DE (1)	DE60134866D1 (de)
ES (1)	ES2309086T3 (de)
GB (1)	GB0023008D0 (de)
HU (1)	HUP0301180A3 (de)
IL (1)	IL154947A0 (de)
MX (1)	MXPA03002453A (de)
MY (1)	MY138978A (de)
NO (1)	NO20031274L (de)
NZ (1)	NZ524792A (de)
PL (1)	PL360895A1 (de)
TW (1)	TWI287453B (de)
WO (1)	WO2002024225A1 (de)
ZA (1)	ZA200302231B (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
ES2628744T3 (es)	1998-05-22	2017-08-03	Ottawa Hospital Research Institute	Métodos y productos para inducir inmunidad en mucosas
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
GB0206461D0 (en) *	2002-03-19	2002-05-01	Glaxo Group Ltd	Improvements in vaccination
DE60335350D1 (de) *	2002-03-19	2011-01-27	Powderject Res Ltd	Adjuvantien für dns impstoffe basierend auf imidazochinoline
DE60325838D1 (de) *	2002-03-19	2009-03-05	Glaxo Group Ltd	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
ES2355819T3 (es) *	2002-08-15	2011-03-31	3M Innovative Properties Company	Composiciones inmunoestimuladoras y métodos para estimular una respuesta inmune.
AU2003301052A1 (en)	2002-12-20	2004-07-22	3M Innovative Properties Company	Aryl / hetaryl substituted imidazoquinolines
US7731967B2 (en)	2003-04-30	2010-06-08	Novartis Vaccines And Diagnostics, Inc.	Compositions for inducing immune responses
TW200510412A (en) *	2003-08-12	2005-03-16	3M Innovative Properties Co	Oxime substituted imidazo-containing compounds
JP2007503268A (ja) *	2003-08-25	2007-02-22	スリーエムイノベイティブプロパティズカンパニー	免疫応答修飾化合物の送達
WO2005018574A2 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
AR045529A1 (es)	2003-08-27	2005-11-02	3M Innovative Properties Co	Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
CA2537763A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
WO2005032484A2 (en) *	2003-10-03	2005-04-14	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
JP2007511527A (ja)	2003-11-14	2007-05-10	スリーエムイノベイティブプロパティズカンパニー	オキシム置換イミダゾ環化合物
EP1682544A4 (de) *	2003-11-14	2009-05-06	3M Innovative Properties Co	Hydroxylaminsubstituierte imidazo-ringverbindungen
AU2004293078B2 (en)	2003-11-25	2012-01-19	3M Innovative Properties Company	Substituted imidazo ring systems and methods
US8802853B2 (en) *	2003-12-29	2014-08-12	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699788A2 (de) *	2003-12-30	2006-09-13	3M Innovative Properties Company	Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
EP1730143A2 (de) *	2004-03-24	2006-12-13	3M Innovative Properties Company	Amidsubstituierte imidazopyridine, imidazochinoline und imidazonaphthyridine
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
US7897609B2 (en) *	2004-06-18	2011-03-01	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
EP1804583A4 (de) *	2004-10-08	2009-05-20	3M Innovative Properties Co	Adjuvans für dna-impfstoffe
DE102004049223A1 (de)	2004-10-08	2006-04-20	Johannes-Gutenberg-Universität Mainz	Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20110070575A1 (en) *	2004-12-08	2011-03-24	Coley Pharmaceutical Group, Inc.	Immunomodulatory Compositions, Combinations and Methods
WO2006083440A2 (en)	2004-12-30	2006-08-10	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005322898B2 (en) *	2004-12-30	2011-11-24	3M Innovative Properties Company	Chiral fused (1,2)imidazo(4,5-c) ring compounds
WO2006071997A2 (en) *	2004-12-30	2006-07-06	3M Innovative Properties Company	Treatment for cutaneous metastases
WO2006084251A2 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune reponse modifiers
US7968563B2 (en)	2005-02-11	2011-06-28	3M Innovative Properties Company	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2009504803A (ja)	2005-08-22	2009-02-05	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｔｌｒアゴニスト
CN101300254A (zh) *	2005-09-09	2008-11-05	科利制药集团公司	N－{2－[4－氨基－2－(乙氧基甲基)－1H－咪唑并[4,5－c]喹啉－1－基]－1,1－二甲基乙基}甲磺酰胺的酰胺和氨基甲酸酯衍生物和方法
ZA200803029B (en) *	2005-09-09	2009-02-25	Coley Pharm Group Inc	Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
KR20080083270A (ko)	2005-11-04	2008-09-17	콜레이 파마시티컬 그룹, 인코포레이티드	하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
EP3085373A1 (de)	2006-02-22	2016-10-26	3M Innovative Properties Company	Konjugate zur modifizierung von immunreaktionen
WO2007106854A2 (en) *	2006-03-15	2007-09-20	Coley Pharmaceutical Group, Inc.	Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007106852A2 (en)	2006-03-15	2007-09-20	Coley Pharmaceutical Group, Inc.	Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
JP2009534428A (ja) *	2006-04-25	2009-09-24	インターツェル・アクチェンゲゼルシャフト	Ｈｃｖワクチン接種
US20090060928A1 (en) *	2006-05-26	2009-03-05	Jean-Claude Bystryn	Topical Toll Like Receptor Ligands as Vaccine Adjuvants
EP2029597A4 (de)	2006-05-31	2011-11-23	Univ California	Purinanaloga
WO2007147529A2 (en) *	2006-06-20	2007-12-27	Transgene S.A.	Recombinant viral vaccine
JP5564249B2 (ja)	2006-06-23	2014-07-30	アレシア・バイオセラピューティクス・インコーポレーテッド	癌に関与するポリヌクレオチド配列およびポリペプチド配列
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN100450484C (zh) *	2006-10-11	2009-01-14	北京科信必成医药科技发展有限公司	一种咪喹莫特混悬溶液及其凝胶剂
DK2510946T3 (en)	2007-02-07	2015-11-02	Univ California	Conjugates of synthetic fluorescent agonists and their applications
CN103736086A (zh) *	2007-02-15	2014-04-23	曼康公司	用于增强t细胞应答的方法
US8709445B2 (en)	2007-07-31	2014-04-29	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists
US8815253B2 (en)	2007-12-07	2014-08-26	Novartis Ag	Compositions for inducing immune responses
CN104829714A (zh)	2008-11-03	2015-08-12	阿莱斯亚生物疗法股份有限公司	特异性地阻滞肿瘤抗原的生物活性的抗体
WO2010088924A1 (en)	2009-02-06	2010-08-12	Telormedix Sa	Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2011068226A1 (ja) *	2009-12-03	2011-06-09	株式会社アウレオ	マクロファージ貪食能活性化組成物および／またはマクロファージにおけるサイトカイン産生促進組成物
CN101850117B (zh) *	2010-06-03	2012-05-30	国家兽用生物制品工程技术研究中心	一种复方免疫佐剂及疫苗
SI2606047T1 (sl)	2010-08-17	2017-04-26	3M Innovative Properties Company	Lipidirani sestavki spojine, ki modificira imunski odgovor, formulacije in postopki
RS59080B1 (sr)	2011-03-31	2019-09-30	Adc Therapeutics Sa	Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
EP2717919B1 (de)	2011-06-03	2016-08-03	3M Innovative Properties Company	Heterobifunktionale linker mit polyethylenglykolsegmenten und daraus hergestellte immunantwort-modifizierende konjugate
JP6415979B2 (ja)	2011-06-03	2018-10-31	スリーエムイノベイティブプロパティズカンパニー	ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
LT2802351T (lt)	2012-01-09	2019-06-25	Adc Therapeutics Sa	Agentai, skirti trigubai neigiamo krūties vėžio gydymui
GB201310578D0 (en)	2013-06-13	2013-07-31	Univ Nottingham Trent	Electroactive actuators
CN105491982B (zh)	2013-08-12	2019-09-10	3M创新有限公司	用于增强透皮递送的肽
CN108366866A (zh)	2015-10-12	2018-08-03	瑞弗罗医疗公司	具有突出的药物递送特征部的支架以及相关的系统和方法
US10533007B2 (en)	2016-04-19	2020-01-14	Innate Tumor Immunity, Inc.	NLRP3 modulators
CN109071535B (zh)	2016-04-19	2021-10-08	先天肿瘤免疫公司	Nlrp3调节剂
US11697851B2 (en)	2016-05-24	2023-07-11	The Regents Of The University Of California	Early ovarian cancer detection diagnostic test based on mRNA isoforms
TWI674261B (zh)	2017-02-17	2019-10-11	美商英能腫瘤免疫股份有限公司	Nlrp3 調節劑
WO2018217897A1 (en) *	2017-05-23	2018-11-29	David Weiner	Compositions and method for inducing an immune response
KR20200051778A (ko)	2017-09-13	2020-05-13	사노피 파스퇴르	인간 시토메갈로바이러스 면역원성 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL105325A (en) *	1992-04-16	1996-11-14	Minnesota Mining & Mfg	Immunogen/vaccine adjuvant composition
BR9712366A (pt) *	1996-10-23	1999-08-31	American Home Prod	Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
GB9818627D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Improvements in dva vaccination

2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
2001
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active Expired - Fee Related
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 EP EP01967535A patent/EP1318835B1/de not_active Revoked
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en not_active Ceased
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040076633A1 (en)	2004-04-22
BR0113982A (pt)	2003-08-19
ES2309086T3 (es)	2008-12-16
CN1473051A (zh)	2004-02-04
AU8790801A (en)	2002-04-02
IL154947A0 (en)	2003-10-31
TWI287453B (en)	2007-10-01
MY138978A (en)	2009-08-28
ZA200302231B (en)	2004-05-05
HK1057700A1 (en)	2004-04-16
AU2001287908B2 (en)	2005-06-30
KR100876263B1 (ko)	2008-12-26
CZ2003792A3 (cs)	2004-12-15
ATE401097T1 (de)	2008-08-15
CN1197620C (zh)	2005-04-20
US20070248614A1 (en)	2007-10-25
WO2002024225A1 (en)	2002-03-28
NO20031274D0 (no)	2003-03-19
NZ524792A (en)	2004-09-24
AR035586A1 (es)	2004-06-16
HUP0301180A2 (hu)	2004-03-01
GB0023008D0 (en)	2000-11-01
CA2422863A1 (en)	2002-03-28
PL360895A1 (en)	2004-09-20
MXPA03002453A (es)	2003-06-19
EP1318835A1 (de)	2003-06-18
NO20031274L (no)	2003-05-19
KR20040023566A (ko)	2004-03-18
HUP0301180A3 (en)	2005-11-28
JP2004509150A (ja)	2004-03-25
US20110002953A1 (en)	2011-01-06
EP1318835B1 (de)	2008-07-16

Publication	Publication Date	Title
DE60134866D1 (de)	2008-08-28	Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung
DE60334277D1 (de)	2010-11-04	Verwendung von Algenproteinen in Kosmetika
DE60111534D1 (de)	2005-07-21	Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
EP1294513A4 (de)	2005-11-23	Lokalisationsspezifische kovalente biokonjugation von proteinen
DE50207852D1 (de)	2006-09-28	Verwendung von fettalkoholethoxylaten als penetrationsförderer
ATE329987T1 (de)	2006-07-15	Verwendung von fischer-tropsch/crackfraktion- gemischen zur erzielung niedriger emissionen
ATE311900T1 (de)	2005-12-15	Adjuvanzien zur verwendung in impfstoffen
ATE280163T1 (de)	2004-11-15	Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
EP1418940A4 (de)	2006-09-20	Dna expressionsvektoren und verwendungsverfahren
DE50111690D1 (de)	2007-02-01	2-acyl-indolderivate und deren verwendung als antitumormittel
EP1424392A4 (de)	2004-11-24	Neue sekretionsproteine und dna dafür
DE50107834D1 (de)	2005-12-01	Dispergierung von pigmenten in polyolefinen
DE60136400D1 (de)	2008-12-11	Reinigung von hbv-Antigenen zur Verwendung in Impfstoffen
DE50006526D1 (de)	2004-06-24	Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs
DE60112148T2 (de)	2006-06-14	Verwendung von (Per)fluoroetherverbindungen als Zusatzstoffe in Formulierungen zur Holzbehandlung
EP1293568A4 (de)	2005-10-26	Protein und dessen dns
DK1328289T3 (da)	2008-12-15	Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
DE10290563D2 (de)	2004-04-29	Mittel zur Hemmung von Tumorzellen
DE50010237D1 (de)	2005-06-09	Verwendung von pit-emulsionen in fermentationsverfahren
EP1490396A4 (de)	2006-04-19	Immunogene hiv-peptide zur verwendung als reagentien und impfstoffe
EP1366056A4 (de)	2003-12-03	Zubereitung von deoxynukleoside
NO20030821D0 (no)	2003-02-21	Gener og proteiner, og deres anvendelse
DE50203046D1 (de)	2005-06-16	Verwendung von Esterquats
ITMI20012482A0 (it)	2001-11-26	Diraspatore separatore-selezionatore di uva
EP1457557A4 (de)	2005-12-28	Neue proteine und deren dnas

Legal Events

Date	Code	Title	Description
2009-07-02	8363	Opposition against the patent